NCT05740813 - HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 | Biotech Hunter

Enrollment

310

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

October 3, 2024

Study Completion Date

October 3, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

ABBV-CLS-7262 Dose 1

ABBV-CLS-7262 is administered orally once per day for 24 weeks.

DRUG

ABBV-CLS-7262 Dose 2

ABBV-CLS-7262 is administered orally once per day for 24 weeks.

DRUG

Matching Placebo

Matching placebo is administered orally once per day for 24 weeks.

Trial Locations (1)

Healey Center for ALS at Mass General, Boston